These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 28634123)

  • 1. Clinical Utility of Chromosomal Aneusomy in Individuals at High Risk of Lung Cancer.
    Barón AE; Kako S; Feser WJ; Malinowski H; Merrick D; Garg K; Malkoski S; Pretzel S; Siegfried JM; Franklin WA; Miller Y; Wolf HJ; Varella-Garcia M
    J Thorac Oncol; 2017 Oct; 12(10):1512-1523. PubMed ID: 28634123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The detection of chromosomal aneusomy by fluorescence in situ hybridization in sputum predicts lung cancer incidence.
    Varella-Garcia M; Schulte AP; Wolf HJ; Feser WJ; Zeng C; Braudrick S; Yin X; Hirsch FR; Kennedy TC; Keith RL; Barón AE; Belinsky SA; Miller YE; Byers T; Franklin WA
    Cancer Prev Res (Phila); 2010 Apr; 3(4):447-53. PubMed ID: 20332298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chromosomal aneusomy in bronchial high-grade lesions is associated with invasive lung cancer.
    Jonsson S; Varella-Garcia M; Miller YE; Wolf HJ; Byers T; Braudrick S; Kiatsimkul P; Lewis M; Kennedy TC; Keith RL; Bjornsson J; McWilliams A; Lam S; Hirsch FR; Franklin WA
    Am J Respir Crit Care Med; 2008 Feb; 177(3):342-7. PubMed ID: 17989344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lung cancer probability in patients with CT-detected pulmonary nodules: a prespecified analysis of data from the NELSON trial of low-dose CT screening.
    Horeweg N; van Rosmalen J; Heuvelmans MA; van der Aalst CM; Vliegenthart R; Scholten ET; ten Haaf K; Nackaerts K; Lammers JW; Weenink C; Groen HJ; van Ooijen P; de Jong PA; de Bock GH; Mali W; de Koning HJ; Oudkerk M
    Lancet Oncol; 2014 Nov; 15(12):1332-41. PubMed ID: 25282285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and validation of a plasma biomarker panel for discerning clinical significance of indeterminate pulmonary nodules.
    Daly S; Rinewalt D; Fhied C; Basu S; Mahon B; Liptay MJ; Hong E; Chmielewski G; Yoder MA; Shah PN; Edell ES; Maldonado F; Bungum AO; Borgia JA
    J Thorac Oncol; 2013 Jan; 8(1):31-6. PubMed ID: 23201823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multi-target interphase fluorescence in situ hybridization assay increases sensitivity of sputum cytology as a predictor of lung cancer.
    Varella-Garcia M; Kittelson J; Schulte AP; Vu KO; Wolf HJ; Zeng C; Hirsch FR; Byers T; Kennedy T; Miller YE; Keith RL; Franklin WA
    Cancer Detect Prev; 2004; 28(4):244-51. PubMed ID: 15350627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Occurrence and lung cancer probability of new solid nodules at incidence screening with low-dose CT: analysis of data from the randomised, controlled NELSON trial.
    Walter JE; Heuvelmans MA; de Jong PA; Vliegenthart R; van Ooijen PMA; Peters RB; Ten Haaf K; Yousaf-Khan U; van der Aalst CM; de Bock GH; Mali W; Groen HJM; de Koning HJ; Oudkerk M
    Lancet Oncol; 2016 Jul; 17(7):907-916. PubMed ID: 27283862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gain of the EGFR gene located on 7p12 is a frequent and early event in squamous cell carcinoma of the lung.
    Kang JU; Koo SH; Kwon KC; Park JW; Jung SS
    Cancer Genet Cytogenet; 2008 Jul; 184(1):31-7. PubMed ID: 18558286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chromosomal abnormalities in non-small cell lung carcinomas and in bronchial epithelia of high-risk smokers detected by multi-target interphase fluorescence in situ hybridization.
    Romeo MS; Sokolova IA; Morrison LE; Zeng C; Barón AE; Hirsch FR; Miller YE; Franklin WA; Varella-Garcia M
    J Mol Diagn; 2003 May; 5(2):103-12. PubMed ID: 12707375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors Associated with a Positive Baseline Screening Exam Result in the National Lung Screening Trial.
    Balekian AA; Tanner NT; Fisher JM; Silvestri GA; Gould MK
    Ann Am Thorac Soc; 2016 Sep; 13(9):1568-74. PubMed ID: 27387658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of lung cancer through low-dose CT screening (NELSON): a prespecified analysis of screening test performance and interval cancers.
    Horeweg N; Scholten ET; de Jong PA; van der Aalst CM; Weenink C; Lammers JW; Nackaerts K; Vliegenthart R; ten Haaf K; Yousaf-Khan UA; Heuvelmans MA; Thunnissen E; Oudkerk M; Mali W; de Koning HJ
    Lancet Oncol; 2014 Nov; 15(12):1342-50. PubMed ID: 25282284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Copy number gains on 5p15, 6p11-q11, 7p12, and 8q24 are rare in sputum cells of individuals at high risk of lung cancer.
    Kettunen E; Salmenkivi K; Vuopala K; Toljamo T; Kuosma E; Norppa H; Knuutila S; Kaleva S; Huuskonen MS; Anttila S
    Lung Cancer; 2006 Nov; 54(2):169-76. PubMed ID: 16935392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of indeterminate pulmonary nodules detected in lung cancer screening: Diagnostic accuracy of FDG PET/CT.
    Garcia-Velloso MJ; Bastarrika G; de-Torres JP; Lozano MD; Sanchez-Salcedo P; Sancho L; Nuñez-Cordoba JM; Campo A; Alcaide AB; Torre W; Richter JA; Zulueta JJ
    Lung Cancer; 2016 Jul; 97():81-6. PubMed ID: 27237032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contribution of a Blood-Based Protein Biomarker Panel to the Classification of Indeterminate Pulmonary Nodules.
    Ostrin EJ; Bantis LE; Wilson DO; Patel N; Wang R; Kundnani D; Adams-Haduch J; Dennison JB; Fahrmann JF; Chiu HT; Gazdar A; Feng Z; Yuan JM; Hanash SM
    J Thorac Oncol; 2021 Feb; 16(2):228-236. PubMed ID: 33137463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of chronic obstructive pulmonary disease in lung cancer screening computed tomographic scans.
    Mets OM; Buckens CF; Zanen P; Isgum I; van Ginneken B; Prokop M; Gietema HA; Lammers JW; Vliegenthart R; Oudkerk M; van Klaveren RJ; de Koning HJ; Mali WP; de Jong PA
    JAMA; 2011 Oct; 306(16):1775-81. PubMed ID: 22028353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A lung cancer risk classifier comprising genome maintenance genes measured in normal bronchial epithelial cells.
    Yeo J; Crawford EL; Zhang X; Khuder S; Chen T; Levin A; Blomquist TM; Willey JC
    BMC Cancer; 2017 May; 17(1):301. PubMed ID: 28464886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High Prevalence of Concomitant Oncogene Mutations in Prospectively Identified Patients with ROS1-Positive Metastatic Lung Cancer.
    Wiesweg M; Eberhardt WEE; Reis H; Ting S; Savvidou N; Skiba C; Herold T; Christoph DC; Meiler J; Worm K; Kasper S; Theegarten D; Hense J; Hager T; Darwiche K; Oezkan F; Aigner C; Welter S; Kühl H; Stuschke M; Schmid KW; Schuler M
    J Thorac Oncol; 2017 Jan; 12(1):54-64. PubMed ID: 27575422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of automated lung nodule detection on low-dose computed tomography scans from a lung cancer screening program(1).
    Armato SG; Roy AS; Macmahon H; Li F; Doi K; Sone S; Altman MB
    Acad Radiol; 2005 Mar; 12(3):337-46. PubMed ID: 15766694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between nodule count and lung cancer probability in baseline CT lung cancer screening: The NELSON study.
    Heuvelmans MA; Walter JE; Peters RB; Bock GH; Yousaf-Khan U; Aalst CMV; Groen HJM; Nackaerts K; Ooijen PMV; Koning HJ; Oudkerk M; Vliegenthart R
    Lung Cancer; 2017 Nov; 113():45-50. PubMed ID: 29110848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Limited value of shape, margin and CT density in the discrimination between benign and malignant screen detected solid pulmonary nodules of the NELSON trial.
    Xu DM; van Klaveren RJ; de Bock GH; Leusveld A; Zhao Y; Wang Y; Vliegenthart R; de Koning HJ; Scholten ET; Verschakelen J; Prokop M; Oudkerk M
    Eur J Radiol; 2008 Nov; 68(2):347-52. PubMed ID: 17920800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.